Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PRCT
stocks logo

PRCT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
93.70M
+37.32%
-0.323
-7.86%
91.96M
+32.96%
-0.321
-28.57%
102.11M
+28.95%
-0.277
-20.82%
Estimates Revision
The market is revising Downward the revenue expectations for PROCEPT BioRobotics Corporation (PRCT) for FY2025, with the revenue forecasts being adjusted by -0.02% over the past three months. During the same period, the stock price has changed by -12.91%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.02%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.65%
In Past 3 Month
Stock Price
Go Down
down Image
-12.91%
In Past 3 Month
Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 54.57 USD with a low forecast of 50.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 54.57 USD with a low forecast of 50.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 35.430
sliders
Low
50.00
Averages
54.57
High
65.00
Current: 35.430
sliders
Low
50.00
Averages
54.57
High
65.00
Morgan Stanley
Patrick Wood
Overweight
downgrade
$56 -> $51
2025-12-02
New
Reason
Morgan Stanley
Patrick Wood
Price Target
$56 -> $51
2025-12-02
New
downgrade
Overweight
Reason
Morgan Stanley analyst Patrick Wood lowered the firm's price target on Procept BioRobotics to $51 from $56 and keeps an Overweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
TD Cowen
Buy
downgrade
$85 -> $50
2025-11-05
Reason
TD Cowen
Price Target
$85 -> $50
2025-11-05
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Procept BioRobotics to $50 from $85 and keeps a Buy rating on the shares. The firm said the stock reaction to its inline sales guidance seems overdone and the believe the company is being conservative.
Piper Sandler
Matt O'Brien
Overweight
downgrade
$55 -> $50
2025-11-05
Reason
Piper Sandler
Matt O'Brien
Price Target
$55 -> $50
2025-11-05
downgrade
Overweight
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on Procept BioRobotics to $50 from $55 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that beat on sales and adjusted EBITDA. Management reiterated FY25 guidance and introduced FY26 sales guidance that brackets the Street's estimate. Piper suspects bears will focus on the soft utilization performance in the quarter and inventory destocking. That said, the firm believes these items reflect some of the organizational changes in the business, which could create transient issues but ultimately set up the business for positive momentum looking forward.
Wells Fargo
Overweight
downgrade
$58 -> $51
2025-11-05
Reason
Wells Fargo
Price Target
$58 -> $51
2025-11-05
downgrade
Overweight
Reason
Wells Fargo lowered the firm's price target on Procept BioRobotics to $51 from $58 and keeps an Overweight rating on the shares. The firm notes the company's Q3 sales beat, but it lowered Q4 guide and provided a 2026 sales outlook with midpoint below Street. The utilization and capital spend commentary raise caution, but Wells believes that Procept commercial reorganization can support upside with an attractive valuation.
Truist
Buy
downgrade
$64 -> $50
2025-10-15
Reason
Truist
Price Target
$64 -> $50
2025-10-15
downgrade
Buy
Reason
Truist lowered the firm's price target on Procept BioRobotics to $50 from $64 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results in MedTech. The firm expects "healthy" Q3 revenue and earnings across its coverage but also braces for "stock volatility", with new money feeling notably absent from the space, the analyst tells investors in a research note. Similar to Q2, specialist and fund positioning could be poised to drive excessive reactions on anything counter to crowded positioning, Truist states, adding that it is more inclined to be positive on "cleaner" names where there is less perceived controversy heading into the quarter.
Oppenheimer
Suraj Kalia
Perform -> Outperform
upgrade
$60
2025-09-02
Reason
Oppenheimer
Suraj Kalia
Price Target
$60
2025-09-02
upgrade
Perform -> Outperform
Reason
Oppenheimer analyst Suraj Kalia upgraded Procept BioRobotics to Outperform from Perform with a $60 price target after meeting with management. The firm believes the share selloff is overdone and Procept's risk/reward is attractive for longer-horizon growth investors. The company's reimbursement uncertainty has been mitigated now that the proposed current procedural terminology rates are out and the management changes seem "more benign than originally feared," the analyst tells investors in a research note. Opco believes Procept's guidance raise seems conservative.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Procept Biorobotics Corp (PRCT.O) is -29.64, compared to its 5-year average forward P/E of -27.69. For a more detailed relative valuation and DCF analysis to assess Procept Biorobotics Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-27.69
Current PE
-29.64
Overvalued PE
-13.63
Undervalued PE
-41.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-51.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-9.88
Undervalued EV/EBITDA
-93.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.42
Current PS
0.00
Overvalued PS
22.18
Undervalued PS
6.66
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 465.92% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

PRCT News & Events

Events Timeline

(ET)
2025-11-04
16:40:16
Procept BioRobotics projects FY26 revenue between $410M and $430M, aligning with consensus of $426.95M.
select
2025-11-04
16:39:34
Procept BioRobotics supports FY25 revenue forecast of $325.5M, slightly below consensus of $326.53M.
select
2025-11-04
16:38:28
Procept BioRobotics announces Q3 earnings per share of 38 cents, below consensus estimate of 42 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-21NASDAQ.COM
PROCEPT BioRobotics to Highlight Aquablation Expansion at Upcoming Piper Sandler Event

  • Company Presentation: PROCEPT BioRobotics Corp. will present at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025, focusing on its Aquablation therapy and HYDROS Robotic System.

  • Financial Performance: For Q3 2025, PROCEPT reported a net loss of $21.4 million, despite a 43% increase in revenue to $83.3 million, driven by strong demand for its products.

  • Revenue Growth: U.S. revenue rose to $73.9 million, a 42% increase from the previous year, while international revenue grew by 53% to $9.4 million, indicating strong market adoption.

  • Future Outlook: The company anticipates full-year revenue of approximately $325.5 million for fiscal 2025, up from $224.5 million in 2024, supported by a solid cash position of $297.3 million.

[object Object]
Preview
6.0
11-06Benzinga
TD Cowen Keeps Buy Rating on PROCEPT BioRobotics, Reduces Price Target to $50

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.

  • Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.

[object Object]
Preview
4.0
10-21Yahoo Finance
Truist Reduces Price Target for PROCEPT BioRobotics Corporation (PRCT) to $50 from $64, Maintains Buy Rating

  • Price Target Adjustment: Truist has reduced the price target for PROCEPT BioRobotics Corporation (NASDAQ:PRCT) from $64 to $50 while maintaining a Buy rating, anticipating healthy Q3 earnings but also potential stock volatility.

  • Company Overview: PROCEPT BioRobotics is a surgical robotics company focused on urology, known for its AquaBeam Robotic System, which is used in minimally invasive surgeries. Despite its potential, some analysts suggest that certain AI stocks may offer better investment opportunities.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Procept Biorobotics Corp (PRCT) stock price today?

The current price of PRCT is 35.43 USD — it has increased 6.78 % in the last trading day.

arrow icon

What is Procept Biorobotics Corp (PRCT)'s business?

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.

arrow icon

What is the price predicton of PRCT Stock?

Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 54.57 USD with a low forecast of 50.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Procept Biorobotics Corp (PRCT)'s revenue for the last quarter?

Procept Biorobotics Corp revenue for the last quarter amounts to 83.33M USD, increased 42.76 % YoY.

arrow icon

What is Procept Biorobotics Corp (PRCT)'s earnings per share (EPS) for the last quarter?

Procept Biorobotics Corp. EPS for the last quarter amounts to -0.38 USD, decreased -5.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Procept Biorobotics Corp (PRCT)'s fundamentals?

The market is revising Downward the revenue expectations for PROCEPT BioRobotics Corporation (PRCT) for FY2025, with the revenue forecasts being adjusted by -0.02% over the past three months. During the same period, the stock price has changed by -12.91%.
arrow icon

How many employees does Procept Biorobotics Corp (PRCT). have?

Procept Biorobotics Corp (PRCT) has 756 emplpoyees as of December 05 2025.

arrow icon

What is Procept Biorobotics Corp (PRCT) market cap?

Today PRCT has the market capitalization of 1.98B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free